Ontorpacept

Names

[ CAS No. ]:
2131089-46-6

[ Name ]:
Ontorpacept

Biological Activity

[Description]:

Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Others >> Others

[In Vitro]

Ontorpacept (0.001-1000 nmol/L；2 h) 在急性髓性白血病，骨髓增生异常综合征，多发性骨髓瘤，B 细胞急性淋巴细胞白血病和 T 细胞急性淋巴细胞白血病患者的肿瘤细胞样本中，剂量依赖性地增加肿瘤细胞的巨噬细胞吞噬作用，平均 EC50 为 10 nmol/L[1]。

[In Vivo]

Ontorpacept (8 mg/kg；腹腔注射，每周 3 次，共 4 周) 在 SCID 小鼠急性髓性白血病异种移植模型中具有抗肿瘤活性[1]。 Animal Model: NOD.SCID mice with AML cell transplants[1] Dosage: 8 mg/kg Administration: Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks Result: Significantly reduced the tumor growth in bone marrow and spleen.

[References]

[1]. Petrova PS, et al. TTI-621 (SIRPαFc): A CD47-Blocking Innate Immune Checkpoint Inhibitor with Broad Antitumor Activity and Minimal Erythrocyte Binding. Clin Cancer Res. 2017 Feb 15;23(4):1068-1079.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.